Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Finland

Coordination and Support Action · Finished

SightLeaders StemSight: curing blindness with stem cells

Coordinator
Stemsight Oy, Finland
Runs
1 June 2023 to 31 May 2024
Status
Finished
EU funding
€75k
Total cost
—
Partners
1 organisations in 1 countries
Type
Coordination and Support Action
Grant agreement
101113810

What the project is doing

In the project's own words, from its summary on CORDIS.

StemSight is developing off-the-shelf stem cell therapies to cure blindness. We aim to solve the global shortage of corneal donor tissue by producing high-quality tissue products using allogeneic induced pluripotent stem cells (iPSCs) and biomaterials. Our lead product is aimed at a rare but severe form of corneal blindness, limbal stem cell deficiency (LSCD), for which there are currently no valid treatment options. The company's innovations have arisen from extensive academic research, and the company has spun out from Tampere University, Finland in 2021.

StemSight is a rare kind of deep-tech startup, as all of its scientific founders are women.

Topics

Who is involved

OrganisationCityCountryRole
Stemsight OyTampereFinlandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI